Showing 5491-5500 of 9753 results for "".
- Time Matters When Saving Skin During FLASH Radiotherapyhttps://practicaldermatology.com/news/time-matters-when-saving-skin-during-flash-radiotherapy/2461966/Multiple beams and intervals in delivery during FLASH proton therapy treatment may reduce skin-saving effects in preclinical models, according to a study in the International Journal of Radiation
- New Kerecis Medical-Fish-Skin Product Approved by Medicare Administrative Contractorshttps://practicaldermatology.com/news/new-kerecis-medical-fish-skin-product-approved-by-medicare-administrative-contractors/2461961/Multiple leading Medicare Administrative Contractors have approved Kerecis Shield, the new fish-skin wound-treatment product. This means that physicians in private clinics will not need to submit invoices for reimbursement, improving efficiency by eliminating a step in the reimbursement proc
- European Commission Green Lights Opdivo as an Adjuvant Treatment for Completely Resected Stage IIB or IIC Melanomahttps://practicaldermatology.com/news/european-commission-green-lights-opdivo-as-an-adjuvant-treatment-for-completely-resected-stage-iib-or-iic-melanoma/2461960/The European Commission (EC) has approved Opdivo (nivolumab) as a monotherapy for the adjuvant treatment of adults and adolescents 12 years of age and older with stage IIB or IIC melanoma who have undergone complete resection, Bristol Myers Squibb reports. The EC approval cove
- Simpson Lab Awarded $50k Grant from Foundation for Ichthyosis & Related Skin Typeshttps://practicaldermatology.com/news/simpson-lab-awarded-50k-grant-from-foundation-for-ichthyosis-related-skin-types/2461955/Cory Simpson, MD, PhD, received a one-year $50k grant from the Foundation for Ichthyosis & Related Skin Types (FIRST) to support the&
- Paradigm Therapeutics Acquires Late Stage "Breakthrough Therapy" for Treatment of All Subtypes of EBhttps://practicaldermatology.com/news/paradigm-therapeutics-acquires-late-stage-breakthrough-therapy-for-treatment-of-all-subtypes-of-eb/2461948/Paradigm Therapeutics Inc. now has the worldwide rights of SD-101, a topical whole-body treatment for all subtypes of Epidermolysis Bullosa (EB), from Amicus Therapeutics. Terms of the deal have not been disclosed. SD-101 received Rare Pediatric Disease designation&
- Experts to Develop Human Skin Cell Atlashttps://practicaldermatology.com/news/experts-to-develop-human-skin-cell-atlas/2461944/A grassroots movement to establish a Human Skin Cell Atlas is underway, according to a review in the Journal of Investigative Dermatology. To perform its numerous functions and to maintain pr
- La Roche-Posay Is the Official Sunscreen of the US Open for the Second Yearhttps://practicaldermatology.com/news/la-roche-posay-is-the-official-sunscreen-of-the-us-open-for-the-second-year/2461941/La Roche-Posay is continuing its partnership as the exclusive Official Sunscreen Partner of the US Open for the second year in a row. At the 2022 US Open, La Roche-Posay provided access to board-certified dermatologists to educate on sun safety and distributed 300,000 free sunscree
- Immunotherapy Drug Combo Helps Extend Progression-Free Survival in Metastatic Melanomahttps://practicaldermatology.com/news/immunotherapy-drug-combo-helps-extend-progression-free-survival-in-metastatic-melanoma/2461940/Combining two immune checkpoint inhibitors helps overcome resistance to prior PD-1 therapy in patients with metastatic melanoma, a new study shows. The combination of ipilimumab and nivolumab showed a longer progression-free survival, but also a greater overall response rate t
- Inmagene's OX40 mAb Enters POC Study in ADhttps://practicaldermatology.com/news/inmagenes-ox40-mab-enters-poc-study-in-ad/2461934/The first patient has been dosed in a global multicenter proof-of-concept (POC) study of Inmagene Biopharmaceuticals’ IMG-007 in adults with moderate-to-severe atopic dermatitis (AD). The objective of the study is to assess the safety, pharmacokinetics, and efficacy of
- VitaSea Gives Back: Skincare Brand to Donate 100% of their Proceeds from Online Sales to the Maui Strong Fund through September 2023https://practicaldermatology.com/news/vitasea-gives-back-skincare-brand-to-donate-100-of-their-proceeds-from-online-sales-to-the-maui-strong-fund-through-september-2023/2461931/VitaSea is donating 100% of their proceeds from online sales to the